Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 1/20 | 0.53 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.47 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.47 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | SLC18A2 | Q05940 | 3/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3449300 | 0.92 | RORC (0.55) | RORCUSP30CHRM2CHRM4CHRM5 | |
| SCHEMBL5839366 | 0.92 | RORC (0.55) | RORCUSP30CHRM2CHRM4CHRM5 | |
| SCHEMBL7887604 | 0.92 | RORC (0.55) | RORCUSP30CHRM2CHRM4CHRM5 | |
| SCHEMBL1891481 | 0.91 | RORC (0.55) | RORCUSP30CHRM2CHRM4CHRM5 | |
| SCHEMBL21892098 | 0.90 | RORC (0.54) | RORCUSP30CHRM2CHRM4CHRM5 | |
| SCHEMBL3025628 | 0.90 | RORC (0.54) | RORCUSP30CHRM2CHRM4CHRM5 | |
| SCHEMBL5097184 | 0.90 | RORC (0.54) | RORCUSP30CHRM2CHRM4CHRM5 | |
| SCHEMBL2780389 | 0.90 | RORC (0.54) | RORCUSP30CHRM2CHRM4CHRM5 | |
| SCHEMBL5097178 | 0.90 | RORC (0.54) | RORCUSP30CHRM2CHRM4CHRM5 | |
| SCHEMBL2782549 | 0.89 | SLC18A2 (0.53) | RORCUSP30CHRM2CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1189883-B1 | SUBSTITUTED PYRROLIDINES AS CELL ADHESION INHIBITORS | AVENTIS PHARMA LTD (GB) | 2004-11-03 | — | — | EP | disclosed |
| US-6548533-B2 | Pyrrolidine carboxylic Acid or ester derivatives are useful for treating alpha 4 beta 1 mediated cell adhesion | AVENTIS PHARMA LIMITED (GB) | 2003-04-15 | — | — | US | disclosed |
| US-20020094994-A1 | Substituted pyrrolidines | AVENTIS PHARMA LIMITED (GB) | 2002-07-18 | — | — | US | disclosed |
| EP-1189883-A2 | SUBSTITUTED PYRROLIDINES AS CELL ADHESION INHIBITORS | Aventis Pharma Limited (GB) | 2002-03-27 | — | — | EP | disclosed |
| WO-2000068195-A2 | SUBSTITUTED PYRROLIDINES AS CELL ADHESION INHIBITORS | AVENTIS PHARMA LIMITED (GB) | 2000-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020094994-A1 | Substituted pyrrolidines | VCAM1, ITGB1, ITGA1 | RORC 352/4885USP30 4717/4885CHRM2 415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.